Prime’s A-team: managing autoimmune specialty

As specialty clinical program director for autoimmune conditions, Ramona Powell keeps a lot of balls in the air: 80 plus different diseases fit in this category

April 26, 2019
The autoimmune category accounts for 14 percent of Prime’s drug spend. This was second only to diabetes in 2017. In an autoimmune disease, the body’s immune system attacks healthy cells. Common autoimmune conditions include rheumatoid arthritis, psoriasis and Crohn’s disease. Dozens of these conditions are extremely rare, affecting only a small handful of people across the country.

Three of the most common autoimmune drugs account for nearly 10 percent of Prime’s pharmacy drug spend in 2018. And the category continues to grow.

Like a lot of specialty, autoimmune drugs are often covered under the medical benefit. In fact, more than 25 percent of autoimmune specialty drugs are covered under the medical benefit.

Prime studies total cost of care by condition

That makes Prime’s unique connection to its Blue Cross and Blue Shield owners and clients so important. “We were one of the first PBMs to analyze both medical and pharmacy claims for autoimmune conditions, and then look at medical diagnosis codes to determine which drugs were used for which of the major autoimmune conditions,” Ramona said.

“That analysis helped us develop aligned strategies to control the costs of autoimmune drugs and help improve outcomes – whether they are covered under the pharmacy or medical benefit,” Ramona explained.

Many autoimmune drugs are used for several different conditions, but for different reasons. For the same drug, a utilization management program might specify a prior authorization for one autoimmune condition, and step therapy for another condition. “The UM criteria needs to specify the drug and the medical condition.”

Other major programs for the autoimmune category include site of care and reimbursement solutions.

Providing the right care, one patient at a time

“This is where it all comes together.” Ramona Powell explained. “Clinical, research, formulary, trade, benefit design, networks, reporting and analytics,” she lists them off on her fingers. “And all of us are thinking about how to make an impact for the individual patient with what we know. All of us come to the table.”

Related news


September 15, 2023

Prime, Magellan Rx Offer Value Plus to Help States Negotiate Value-Based Contracts for CGTs

Reprinted with permission from MMIT By Angela Maas As more and more high-cost…


September 15, 2023

Prime Therapeutics ranked No. 3 on Minnesota top private companies list

The Minneapolis/St. Paul Business Journal named Prime Therapeutics (Prime) to its annual list,…


September 5, 2023

Prime Together Foundation: Helping students achieve their dreams

Since 2002, Achieve Twin Cities has equipped more than 85,000 high school students…